Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma

Abigail S Chan; Vincent Y Ng; James Snider; Michael E Kallen; Kenneth D Miller

doi:10.7759/cureus.8575

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma

Cureus. 2020 Jun 12;12(6):e8575. doi: 10.7759/cureus.8575.

Authors

Abigail S Chan¹, Vincent Y Ng², James Snider³, Michael E Kallen⁴, Kenneth D Miller^{5

6}

Affiliations

¹ Department of Internal Medicine, Sinai Hospital, Baltimore, USA.
² Department of Orthopedics, University of Maryland Medical Center, Baltimore, USA.
³ Department of Radiation Oncology, Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA.
⁴ Department of Pathology, University of Maryland School of Medicine, Baltimore, USA.
⁵ Department of Medical Oncology, Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, USA.
⁶ Department of Medical Oncology, Sinai Hospital, Baltimore, USA.

Abstract

Hyperprogression associated with immunotherapy has been reported previously with melanoma, non-small cell lung cancer (NSCLC), renal, and urothelial cancers but not with sarcoma. A 63-year old man with a biopsy-proven, localized 13 cm high-grade myxoid/round cell liposarcoma of the thigh was treated with concurrent, neoadjuvant checkpoint inhibitor immunotherapy and radiotherapy. After his subsequent wide surgical resection, he developed small hepatic lesions that rapidly progressed and caused his death, raising the possibility of hyperprogression in this entity.

Keywords: hyperprogression; immunotherapy; soft tissue sarcoma.

Publication types

Case Reports